Marian K Mosior

7595403, Sep 29, 2009

Mar 25, 2004

10/550006

Patrick Irving Eacho - Indianapolis IN, US
Ho-Shen Lin - Indianapolis IN, US
Jose Eduardo Lopez - Fishers IN, US
Marian Kazimierz Mosior - Carmel IN, US
Michael Enrico Richett - Indianapolis IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/428
C07D 275/04

548209, 514373

A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases. (I).

8048880, Nov 1, 2011

May 2, 2008

12/114710

Joaquim Trias - Millbrae CA, US
Colin Hislop - Menlo Park CA, US
Paul Truex - Pleasanton CA, US
Bernadine Fraser - Sunnyvale CA, US
Debra Odink - Oakland CA, US
Scott Chadwick - Redwood City CA, US
Kenneth Gould - Zionsville IN, US
Marian Mosior - Indianapolis IN, US
Patrick Eacho - Indianapolis IN, US

Anthera Pharmaceuticals, Inc. - Hayward CA

A61K 31/535
A61K 31/397
A61K 31/44
A61K 31/40

5142352, 51421002, 514356, 514422, 514423

Administration of sPLAinhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLAinhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLAinhibitors. Significantly, administration of sPLAinhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLAinhibitors and statins resulted in a synergistic decrease in plaque content. Therefore, also provided herein are compositions comprising one or more sPLAinhibitors and one or more compounds used in the treatment of CVD, such as for example statins, and methods of using these compositions to treat dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome.

20060116409, Jun 1, 2006

Mar 25, 2004

10/544908

Patrick Eacho - Indianapolis IN, US
Ho-Shen Lin - Indianapolis IN, US
Jose Lopez - Fishers IN, US
Marian Mosior - Carmel IN, US
Michael Richett - Indianapolis IN, US

A61K 31/42
C07D 261/20

514378000, 548241000

A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.

20060211755, Sep 21, 2006

Mar 25, 2004

10/544910

Patrick Eacho - Indianapolis IN, US
Ho-Shen Lin - Indianapolis IN, US
Jose Lopez - Fishers IN, US
Marian Mosior - Carmel IN, US
Michael Richett - Indianapolis IN, US

Eli Lilly and Company Patent Division - Indianapolis IN

A61K 31/416
C07D 231/56

514405000, 548361500

The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C-Calkyl; C,—C,haloalkyl, CC,2alkenyl, C-Calkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, Calkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—Ca)kyl, C,—Chaloalkyl, ′C-Calkenyl, C2-Ca)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12)000C,—Csalkyl, (CH2)NRR, and C,Calkylcycloalkyl; wherein W and Rare independently selected from hydrogen, C,Calkyl, C-Calkenyl, C-Calkynyl, and C,—C5alkylcycloalkyl; Ris hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—Calkyl, CC,2haloalkyl, alkenyl, C-Calkynyl, C,—Calkylaryl, C,—Calkylcyclohexyl, C, Calkylcyclopentyl, C,—Calkylheterocyclic, (CH2)000H, (CH2)C0(C,—C,o)alkyl, (CH)COO(C,—C)alkyl, (CH2)COO(C-C)alkylaryl, C,—Calkylamino, halo, (CH)CONH, (CH)CONRaR, phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from Calkyl, C,—Chaloalkyl, C-Calkenyl, CCalkynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (CH2)000C,—Csalkyl, and C,—C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,—Calkyl, C,Chaloalkyl, C-Calkenyl, C-Calkynyl, C,—Calkylaryl, C,—Calkylcyclohexyl, C—Caikylcyclopentyl, C,—Calkylheterocyclic, or aryl; or a pharmaceutically acceptable sallvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.